These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 8585168)

  • 1. [Soluble heteroprotein conjugates based on recombinant pro-urokinase for ophthalmology].
    Kol'tsova SV; Boĭko EV; Kuznetsova NP; Danilichev VF
    Vopr Med Khim; 1995; 41(3):13-7. PubMed ID: 8585168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Intraocular hemorrhage of diabetic etiology: current notions on pathogenesis and enzyme therapy].
    Evgrafov VIu; Aliab'eva ZhIu
    Vestn Oftalmol; 1995; 111(4):35-7. PubMed ID: 8604538
    [No Abstract]   [Full Text] [Related]  

  • 3. [Immobilized thrombolytic enzymes and their use in ophthalmology].
    Samsonov GV; Danilichev VF; Kol'tsova SV
    Vopr Med Khim; 1985; 31(4):51-4. PubMed ID: 4049787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics of recombinant pro-urokinase ocular dosage form].
    Aliab'eva ZhIu; Matveev MIu; Evgrafov VIu; Domogatskiĭ SP
    Vestn Oftalmol; 1998; 114(1):38-41. PubMed ID: 9584640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experimental evaluation of the use of recombinant prourokinase and its immobilized forms in the treatment of postoperative fibrinoid syndrome in ophthalmology].
    Boĭko EV; Danilichev VF; Kol'tsova SV
    Biull Eksp Biol Med; 1997 Feb; 123(2):201-4. PubMed ID: 9280496
    [No Abstract]   [Full Text] [Related]  

  • 6. Enhancement of in vitro renaturation of recombinant human pro-urokinase by ampicillin.
    Hua ZC; Dong C; Zhu DX
    Biochem Mol Biol Int; 1996 Aug; 39(6):1093-7. PubMed ID: 8876961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fusion expression of human pro-urokinase with E. coli thioredoxin.
    Sun AL; Hua ZC; Yao J; Yang YH; Yin DQ
    Biochem Mol Biol Int; 1998 Oct; 46(3):479-86. PubMed ID: 9818087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of human recombinant prourokinase(rhpro-UK) on thromboembolic stroke in rats.
    Hao CH; Ding WX; Sun Q; Li XX; Wang WT; Zhao ZY; Tang LD
    Eur J Pharmacol; 2018 Jan; 818():429-434. PubMed ID: 29154937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity.
    Liu JN; Tang W; Sun ZY; Kung W; Pannell R; Sarmientos P; Gurewich V
    Biochemistry; 1996 Nov; 35(45):14070-6. PubMed ID: 8916892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renaturation of recombinant human pro-urokinase expressed in Escherichia coli.
    Hua ZC; Dong C; Zhu DX
    Biochem Biophys Res Commun; 1996 Mar; 220(1):131-6. PubMed ID: 8602832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of glycosylation on the catalytic and fibrinolytic properties of pro-urokinase.
    Lenich C; Pannell R; Henkin J; Gurewich V
    Thromb Haemost; 1992 Nov; 68(5):539-44. PubMed ID: 1455401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Thrombolytic therapy in acute myocardial infarct].
    Bode C; Baumann H; von Hodenberg E; Kübler W
    Med Klin (Munich); 1992 Feb; 87(2):64-9. PubMed ID: 1542285
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effect of electrostatic interactions on formation and properties of soluble heteroprotein conjugates based on proteolytic enzymes].
    Kol'tsova SV
    Bioorg Khim; 1995 Jun; 21(6):408-20. PubMed ID: 7661865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cleavage of pro-urokinase type plasminogen activator by stromelysin-1.
    Orgel D; Schröder W; Hecker-Kia A; Weithmann KU; Kolkenbrock H; Ulbrich N
    Clin Chem Lab Med; 1998 Sep; 36(9):697-702. PubMed ID: 9804393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of prourokinase in different mammalian cells].
    Qian F; Xiao CZ; Gao LH; Zhang ZG; Guo ZX; Yu WY
    Sheng Wu Gong Cheng Xue Bao; 2000 May; 16(3):349-52. PubMed ID: 11059279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thrombolytic drugs in acute myocardial infarct].
    Ambrosioni E; Degli Esposti D
    Cardiologia; 1991 Dec; 36(12 Suppl 1):395-402. PubMed ID: 1841796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RP-HPLC peptide mapping methods for the analysis of recombinant human pro-urokinase.
    Facchetti I; Valla A; Vigevani A
    J Pharm Biomed Anal; 1993 Aug; 11(8):737-44. PubMed ID: 8257739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fibrinolytic agents--who benefits when?].
    Weichert W; Seifried E
    Ther Umsch; 1995 Oct; 52(10):652-60. PubMed ID: 7482376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a recombinant chimeric plasminogen activator composed of Gly-Pro-Arg-Pro tetrapeptide and truncated urokinase-type plasminogen activator expressed in Escherichia coli.
    Hua ZC; Chen XC; Dong C; Zhu DX
    Biochem Biophys Res Commun; 1996 May; 222(2):576-83. PubMed ID: 8670247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of high and low molecular weight single-chain urokinase-type plasminogen activator (pro-urokinase) by thrombin in the presence of thrombomodulin.
    de Munk GA; Molinari A; Rijken DC
    Thromb Haemost; 1993 Jan; 69(1):88. PubMed ID: 8383362
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.